Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:  The macrophage immune checkpoint inhibitor magrolimab in AMLThe STAMP inhibitor asciminib in CML (the ASCEMBL trial)Optimal dosing for the TKI ponatinib in CMLPresenters:Jorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research AcademyAugusta, GeorgiaEunice S. Wang, MDProfessor, OncologyChief, Leukemia ServiceDepartment of MedicineRoswell Park Comprehensive Cancer CenterBuffalo, New YorkContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:https://bit.ly/3tyQ9nG  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.